Triana Biomedicines, Inc.

Who: Roche’s Genentech/Orionis Biosciences What: The companies signed a second deal focused on molecular glue drugs in oncology. Why: The deal expands on an existing partnership between Orionis

AbbVie, Biogen, Pfizer and Novartis have each signed collaborations with biotechs centered on molecular glue degradation in fields such as cancer, immunology and neurology in just the past five months

Who : AbbVie and Neomorph What: The two companies have signed a collaboration and option-to-license deal to develop molecular glue degraders in oncology and immunology. Why: The deal brings togeth

Another day and another deal in the molecular glue degrader (MGD) space has been inked, with Biogen the latest major company keen to explore the potential of protein degradation for previously undrugg